BRPI0502433A - métodos para avaliação e tratamento de cáncer - Google Patents

métodos para avaliação e tratamento de cáncer

Info

Publication number
BRPI0502433A
BRPI0502433A BRPI0502433-1A BRPI0502433A BRPI0502433A BR PI0502433 A BRPI0502433 A BR PI0502433A BR PI0502433 A BRPI0502433 A BR PI0502433A BR PI0502433 A BRPI0502433 A BR PI0502433A
Authority
BR
Brazil
Prior art keywords
methods
treatment
patient
therapy
profiles
Prior art date
Application number
BRPI0502433-1A
Other languages
English (en)
Inventor
Mitch Raponi
Original Assignee
Johnson & Johnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson filed Critical Johnson & Johnson
Publication of BRPI0502433A publication Critical patent/BRPI0502433A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

"MéTODOS PARA AVALIAçãO E TRATAMENTO DE CáNCER". A presente invenção refere-se a métodos para o tratamento de pacientes com câncer e, de preferência, malignidades hematológicas, incluem análise de perfis de expressão do gene e/ou marcadores moleculares de um paciente para determinar se o paciente tem probabilidade de responder ao tratamento com inibidores de farnesil transferase (FTIs) e, opcionalmente, outros produtos terapêuticos. Os métodos também são úteis para o monitoramento da terapia do paciente e para seleção de um curso de terapia. Genes modulados em resposta ao tratamento com FTI são proporcionados e são usados na formulação dos perfis.
BRPI0502433-1A 2004-07-01 2005-07-01 métodos para avaliação e tratamento de cáncer BRPI0502433A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/883,436 US20050003422A1 (en) 2003-07-01 2004-07-01 Methods for assessing and treating cancer

Publications (1)

Publication Number Publication Date
BRPI0502433A true BRPI0502433A (pt) 2006-04-04

Family

ID=35058443

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0502433-1A BRPI0502433A (pt) 2004-07-01 2005-07-01 métodos para avaliação e tratamento de cáncer

Country Status (14)

Country Link
US (1) US20050003422A1 (pt)
EP (1) EP1611890B1 (pt)
JP (1) JP2006014739A (pt)
KR (1) KR20060048684A (pt)
CN (1) CN1721553A (pt)
AR (1) AR049564A1 (pt)
AT (1) ATE440604T1 (pt)
AU (1) AU2005202520A1 (pt)
BR (1) BRPI0502433A (pt)
CA (1) CA2512493A1 (pt)
DE (1) DE602005016189D1 (pt)
DK (1) DK1611890T3 (pt)
MX (1) MXPA05007207A (pt)
PT (1) PT1611890E (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05004971A (es) * 2004-05-06 2005-11-23 Johnson & Jonhson Pronostico para malignidad hematologica.
US12366585B2 (en) 2006-05-18 2025-07-22 Caris Mpi, Inc. Molecular profiling of tumors
WO2008054598A2 (en) * 2006-09-29 2008-05-08 Schering Corporation Panel of biomarkers for prediction of fti efficacy
AU2008225130A1 (en) * 2007-03-12 2008-09-18 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
US7932036B1 (en) 2008-03-12 2011-04-26 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
US8296867B2 (en) * 2008-03-21 2012-10-30 Bauer Hockey, Inc. Helmet for a hockey or lacrosse player
EP3301446B1 (en) * 2009-02-11 2020-04-15 Caris MPI, Inc. Molecular profiling of tumors
US11559540B2 (en) 2010-07-28 2023-01-24 Janssen Pharmaceutica Nv Method of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors
CA2806112C (en) * 2010-07-28 2023-03-21 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors
WO2017184968A1 (en) * 2016-04-22 2017-10-26 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
MX2020001207A (es) * 2017-08-07 2020-03-20 Kura Oncology Inc Metodos de tratamiento del cancer con inhibidores de farnesiltransferasa.
US20210231666A1 (en) * 2018-06-06 2021-07-29 La Jolla Institute For Immunology Cd33 monocytes as a biomarker

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238808A (en) 1984-10-31 1993-08-24 Igen, Inc. Luminescent metal chelate labels and means for detection
US5221605A (en) 1984-10-31 1993-06-22 Igen, Inc. Luminescent metal chelate labels and means for detection
US5310687A (en) 1984-10-31 1994-05-10 Igen, Inc. Luminescent metal chelate labels and means for detection
SK283335B6 (sk) 1995-12-08 2003-06-03 Janssen Pharmaceutica N. V. (Imidazol-5-yl)metyl-2-chinolinónové deriváty, spôsob a medziprodukty na ich prípravu, ich použitie a farmaceutické kompozície na ich báze
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
JP2001505548A (ja) 1996-12-20 2001-04-24 トヴァリシェストヴォ エス オグラニチェンノイ オトヴェトストヴェンノストジュ“タブジュファーム” 凍結乾燥ハイドロクロライド−１β，１０β−エポキシ−１３−ジメチルアミノ−グアヤ−３（４）−エン−６，１２−オリドの生成方法および装置
US6303654B1 (en) 1998-03-12 2001-10-16 Wisconsin Alumni Research Foundation Acyclic monoterpenoid derivatives
AU3316600A (en) * 1999-02-22 2000-09-21 Torben F. Orntoft Gene expression in bladder tumors
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
US20040110792A1 (en) * 2001-10-30 2004-06-10 Mitch Raponi Methods for assessing and treating leukemia
US7473526B2 (en) * 2002-03-29 2009-01-06 Veridex, Llc Breast cancer prognostic portfolio
US20030224422A1 (en) * 2002-04-08 2003-12-04 St. Jude Children's Research Hospital, Inc. Pre-and post therapy gene expression profiling to identify drug targets
EP1502962A3 (en) * 2003-07-01 2006-01-11 Veridex, LLC Methods for assessing and treating cancer

Also Published As

Publication number Publication date
MXPA05007207A (es) 2006-05-22
CN1721553A (zh) 2006-01-18
AU2005202520A1 (en) 2006-01-19
CA2512493A1 (en) 2006-01-01
US20050003422A1 (en) 2005-01-06
DK1611890T3 (da) 2009-11-16
JP2006014739A (ja) 2006-01-19
AR049564A1 (es) 2006-08-16
KR20060048684A (ko) 2006-05-18
EP1611890A1 (en) 2006-01-04
ATE440604T1 (de) 2009-09-15
PT1611890E (pt) 2009-09-29
EP1611890B1 (en) 2009-08-26
DE602005016189D1 (de) 2009-10-08

Similar Documents

Publication Publication Date Title
BRPI0502433A (pt) métodos para avaliação e tratamento de cáncer
Speit et al. Genotoxicity of hyperbaric oxygen
Losso et al. In vitro anti-proliferative activities of ellagic acid
Szalai et al. Anti‐inflammatory effect of recreational exercise in TNBS‐induced colitis in rats: Role of NOS/HO/MPO System
WO2006133420A3 (en) Treatment of patients with cancer therapy
Nikolova et al. Genotoxicity testing: Comparison of the γH2AX focus assay with the alkaline and neutral comet assays
BRPI0503418A (pt) prognóstico para malignidade hematológica
BR0311814A (pt) Método de tratar câncer empregando inibidores de cinase
ATE531725T1 (de) Verfahren zur vorhersage ob nsclc-patienten auf eine behandlung mit einem egfr-tk-hemmer ansprechen
DE60222590D1 (de) Methoden zur feststellung von akute myeloischen leukämie
BR0214840A (pt) Genes
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
BR0108659A (pt) Métodos para tratamento ou prevenção ou profilaxia de câncer de mama, para detecção, diagnóstico e/ou avaliação ou prognóstico quanto ao câncer de mama, para monitoração e/ou estimativa de tratamento do câncer de mama, para identificação da presença ou ausência de células de câncer de mama metastáticas em um amostra biológica e para avaliação ou identificação de compostos, usos de uma ou mais bcmps, de uma composição, de um anticorpo, de ácido nucleico e de um agente que interaja com ou module a atividade de uma ou mais bcmps, vacina, composição, kit e anticorpo
BRPI0412110A (pt) genes regulados no cáncer ovariano como alvos prognósticos e terapêuticos
BRPI0515794A (pt) processos para avaliar pacientes com leucemia mielóide aguda
Kakkar et al. Thrombosis and cancer: implications beyond Trousseau
BRPI0403291A (pt) Métodos para avaliação e tratamento de câncer
Park et al. Acceleration of collagen breakdown by extracellular basic pH in human dermal fibroblasts
Liu et al. Synergistic effect of radon and sodium arsenite on DNA damage in HBE cells
Park Enhanced cell death effects of MAP kinase inhibitors in propyl gallate-treated lung cancer cells are related to increased ROS levels and GSH depletion
Pollack et al. Relationship of tumor DNA-ploidy toserum prostate-specific antigen doubling time after radiotherapy for prostate cancer
BRPI0315735A8 (pt) método para o ensaio de ngf a diagnose in vitro de câncer de mama e uso terapêutico
Chernykh et al. Effect of expression of multidrug resistance genes in newly diagnosed multiple myeloma on the clinical course of the disease
Lu et al. CSF neurochemical study of tardive dyskinesia
Chua et al. Knowledge of the HPV vaccine among South Asian and South Asian-American young adults

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: CONFORME ARTIGO 10O DA RESOLUCAO 124/06, CABE SER ARQUIVADO REFERENTE AO NAO RECOLHIMENTO DA 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2138 DE 27/12/2011.